Altre lingue Otsuka Corporation

Azioni

4768

JP3188200004

Tempo differito Japan Exchange Altri mercati azionari 08:00:00 19/04/2024			Variaz. 5gg	Var. 1 gen.
3.103 ^JPY	-0,74%		-3,51%	+6,76%

09/04	H. Lundbeck, Otsuka Pharmaceutical chiedono l'approvazione della FDA per la terapia combinata contro il PTSD	MT
27/03	La Commissione europea approva Abilify Maintena di Lundbeck e Otsuka come trattamento di mantenimento della schizofrenia	MT

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

H. Lundbeck, Otsuka Pharmaceutical Seek US FDA Nod for PTSD Combination Therapy	09/04
Bourses asiatiques: Tokyo mi-figue, mi-raisin, Hong Kong confiante	02/04
Otsuka Holdings Disposes of 2.32 Billion Yen Worth of Shares as Restricted Stock Compensation	29/03
EU Commission Green-lights Lundbeck, Otsuka's Abilify Maintena as Maintenance Treatment of Schizophrenia	27/03
Sumitomo Pharma Amends Collaboration Agreement with Otsuka Pharmaceutical	18/03
IBio Sells Preclinical PD-1 Antagonist Antibody Program to Otsuka	26/02
Otsuka Holdings' Attributable Profit Down 9.2% 2023 On Impairment Losses	16/02
MÄRKTE ASIEN/Schwach - Zinssenkungshoffnungen schwinden	14/02
MÄRKTE ASIEN/Leichter nach US-Dämpfer für Zinssenkungshoffnungen	14/02
Otsuka Holdings Lowers 2023 Profit Outlook	13/02
Japan's Nikkei cruises to 34-year peak, briefly breaching 38,000 range	13/02
Japan's Nikkei soars to 34-year high on chip shares, earnings	13/02
Phase 3 Trial for Otsuka's Alzheimer's-related Agitation Treatment Fails to Meet Primary Endpoint	13/02
Otsuka's drug for Alzheimer's disease agitation fails in late stage study	13/02
Otsuka Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	01/02
Ionis Pharmaceuticals Says Potential Angioedema Treatment Met Primary Endpoint of Phase 3 Study	22/01
Marchés mondiaux: l'Europe dans le vert avant l'inflation américaine	11/01
Tokyo: le Nikkei au-delà des 35.000 points, une première depuis 34 ans	11/01
Tokyo: le Nikkei finit au-dessus des 35.000 points, une première depuis 34 ans	11/01
Ionis Pharmaceuticals Signs Europe Licensing Deal With Otsuka for Donidalorsen in Hereditary Angioedema	18/12

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Otsuka Corporation

Azioni

4768

JP3188200004

Altre lingue

Filtri